Biohaven Completes Enrollment in RISE3 Trial for Opakalim

Biohaven (BHVN) announced the completion of enrollment in its pivotal Phase 2/3 trial, RISE3, evaluating opakalim for refractory focal epilepsy. Top-line results are expected by late 2026.

By Jeff Lewis Thu, July 9, 2026 at 1:40 PM GMT+3 1 min read · Yahoo Finance · July 9, 2026, 10:40 UTC

Biohaven Completes Enrollment in RISE3 Trial for Opakalim

Tickers: $BHVN

Topics: epilepsy neuroscience pharma

Read the full article at Yahoo Finance

More World news

Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC
Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC